Browse by author
Lookup NU author(s): Dr Claire WoodORCiD, Professor Timothy CheethamORCiD, Professor Simon BaileyORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2026 The AuthorsBackground: We present three patients who developed symptomatic hypercalcaemia following discontinuation of the Type II RAF inhibitor, Tovorafenib. Methods: We report three paediatric cases who had been enrolled in the phase 2 FIREFLY-1 (PNOC026; NCT04775485) Kilburn et al. (2024), which was investigating the safety and efficacy of Tovorafenib monotherapy in patients with relapsed or refractory paediatric low-grade glioma (pLGG) harbouring a KIAA-BRAF-fusion or BRAF V600E mutation. Hypercalcaemia was detected within weeks after discontinuation of Tovorafenib. Results: Adjusted serum calcium concentrations at first presentation were 2.91 mmol/L at 21 days (Patient 1), 3.06 mmol/L at 14 days (Patient 2), and 3.58 mmol/L at 26 days (Patient 3) following cessation of Tovorafenib. Calcium concentrations normalised following treatment with additional fluid and, in two of the patients, a single dose of bisphosphonate. Conclusion: We suspect that the hypercalcaemia reflects a rebound increase in bone turnover following Tovorafenib discontinuation and recommend that monitoring bone biochemistry after treatment cessation be considered as part of management protocols.
Author(s): Mohamed S, Wood CL, Halliday G, Arif T, Fritzberg A, Tuckuviene R, Majiyagbe T, Hassall TE, Nicholls W, McMahon SK, Cheetham T, Bailey S
Publication type: Article
Publication status: Published
Journal: EJC Paediatric Oncology
Year: 2026
Volume: 7
Print publication date: 01/06/2026
Online publication date: 31/01/2026
Acceptance date: 22/01/2026
Date deposited: 14/04/2026
ISSN (electronic): 2772-610X
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.ejcped.2026.100488
DOI: 10.1016/j.ejcped.2026.100488
Altmetrics provided by Altmetric
